JAMA – October 8, 2014

JAMA
October 8, 2014, Vol 312, No. 14
http://jama.jamanetwork.com/issue.aspx

Expanding the Options for Confronting Pandemic Influenza
John J. Treanor, MD1
[+] Author Affiliations
JAMA. 2014;312(14):1401-1402. doi:10.1001/jama.2014.12558.
The majority of physicians and public health practitioners are familiar with the concept that the vast reservoir of influenza A viruses found in migratory waterfowl represent an ongoing threat to emerge in humans and cause widespread disease. Although these avian influenza A viruses, which include all of the known hemagglutinin (H1-H16) and neuraminidase (N1-N9) subtypes, are generally restricted in their ability to replicate in humans, recent work has shown that a minimal number of mutations can result in viruses likely to transmit efficiently from person to person.1,2 The resulting global epidemic or pandemic of influenza would spread rapidly and almost certainly would have massive public health implications. Among the many hemagglutinin subtypes, viruses of the H5 and more recently H7 subtypes are of particular concern because of their demonstrated ability to cause severe disease in humans.3,4 …

.

Contemporary Challenges to Human Health: Infectious Disease Theme Issue
Preeti N. Malani, MD, MSJ

Original Investigation
Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 Adjuvant: A Randomized Clinical Trial
Mark J. Mulligan, MD; David I. Bernstein, MD, MA; Patricia Winokur, MD; Richard Rupp, MD; Evan Anderson, MD; Nadine Rouphael, MD; Michelle Dickey, MS, CRNP; Jack T. Stapleton, MD; Srilatha Edupuganti, MD; Paul Spearman, MD; Dilek Ince, MD; Diana L. Noah, PhD; Heather Hill, MS; Abbie R. Bellamy, PhD; for the DMID 13-0032 H7N9 Vaccine Study Group
Includes: Supplemental Content

Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine With MF59 Adjuvant: A Randomized Clinical Trial
Robert B. Belshe, MD; Sharon E. Frey, MD; Irene L. Graham, MD; Edwin L. Anderson, MD; Lisa A. Jackson, MD; Paul Spearman, MD; Srilatha Edupuganti, MD; Mark J. Mulligan, MD; Nadine Rouphael, MD; Patricia Winokur, MD; Rowena J. Dolor, MD; Christopher W. Woods, MD; Emmanuel B. Walter, MD; Wilbur H. Chen, MD; Christine Turley, MD; Kathryn M. Edwards, MD; C. Buddy Creech, MD; Heather Hill, MS; Abbie R. Bellamy, PhD; for the National Institute of Allergy and Infectious Diseases–Funded Vaccine and Treatment Evaluation Units
Includes: Supplemental Content